InMode Ltd(NASDAQ:INMD) 
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various pr...
Website: https://www.inmodemd.com
Founded: 2008
IPO Price: $14 (Aug 08, 2019)
Full Time Employees: 251
CEO / Co-Founder: Moshe Mizrahy
Sector: Healthcare
Industry: Medical Devices
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
- Minimally Invasive Aesthetic Focus: InMode Ltd develops and sells energy-based devices used in minimally invasive aesthetic and medical procedures, with core demand tied to cosmetic treatment volumes and clinic/spa capital spending.
- Recurring Revenue Mix vs. Capital Equipment Cyclicality: Results are influenced by the balance between higher-ticket system sales (which can be cyclical) and recurring consumables/service revenue (which can smooth performance and support margins).
- International Expansion and Channel Execution Matter: Growth is often driven by penetration in new geographies and productivity of the direct/indirect sales channels; execution on training, marketing, and physician adoption is a key variable.
- Competitive Landscape and Technology Differentiation: Performance depends on maintaining clinical outcomes, safety profile, and technology differentiation amid intense competition in aesthetic devices, alongside ongoing product refresh cycles.
- Regulatory, Reimbursement, and Reputation Risks: As a medical device company, InMode faces regulatory compliance requirements and potential product liability/reputation risks; changes in regulations or adverse events could affect demand and costs.
Bull Thesis:
- Strong Product Portfolio and Innovation Pipeline: InMode boasts a diverse and innovative portfolio of minimally invasive and non-invasive aesthetic solutions, such as Morpheus8, EvolveX, and EmpowerRF. Continuous R&D and introduction of new platforms or enhancements keep them competitive and address evolving market demands, attracting new practitioners and patients.
- High Recurring Revenue from Consumables: A significant portion of InMode's revenue is derived from the sale of consumables (e.g., handpieces, tips) that are required for each procedure performed with their devices. This 'razor-and-blade' model creates a stable and predictable recurring revenue stream once a capital equipment sale is made, enhancing long-term customer value.
- Expanding Global Market Penetration and Practitioner Adoption: InMode continues to expand its global footprint, entering new geographic markets and increasing penetration within existing ones. The company is also successfully targeting a broader range of medical specialties (e.g., OB/GYN, plastic surgery, dermatology), driving wider adoption of its technologies among practitioners seeking effective, high-ROI solutions.
- Robust Profitability and Strong Balance Sheet: Historically, InMode has demonstrated strong profitability with high gross margins and healthy operating income. The company typically maintains a strong balance sheet with significant cash reserves and no debt, providing financial flexibility for R&D, market expansion, and potential share buybacks or dividends.
Bear Thesis:
- Intense Competition and Potential Pricing Pressure: The aesthetic device market is highly competitive, with numerous established players and new entrants offering similar or alternative technologies. This intense competition could lead to pricing pressure on InMode's devices and consumables, potentially eroding profit margins and market share over time.
- Reliance on Discretionary Spending and Macroeconomic Sensitivity: Aesthetic procedures are largely discretionary, making InMode's sales susceptible to macroeconomic downturns, inflation, and changes in consumer confidence. Economic pressures on clinics (e.g., higher interest rates for financing equipment) or on patients' disposable income could lead to reduced demand for devices and treatments.
- Slowing Growth Trajectory Post-Pandemic Boom: After experiencing accelerated growth during and immediately after the pandemic as clinics invested in new technologies, InMode's growth rate may normalize or slow down. Market saturation in key regions or a deceleration in the overall aesthetic market could make it challenging to maintain previous high growth rates.
- Potential for Physician Over-saturation and Diminishing ROI: As more practitioners acquire InMode devices, particularly popular ones like Morpheus8, there's a risk of market over-saturation in certain geographic areas. This could lead to diminishing returns on investment for individual clinics, potentially slowing future device sales as practitioners become more cautious about new capital expenditures.
Main Competitors:
- Cynosure (a division of Hologic, now independent) (Potenza, TempSure, Elite iQ), Cynosure is a direct competitor, offering a broad portfolio of energy-based aesthetic devices. Its Potenza RF microneedling system directly competes with InMode's Morpheus8, while TempSure provides RF skin tightening and Elite iQ offers hair removal and vascular treatments, overlapping with InMode's multi-application platforms.
- Cutera, Inc. ($CUTR) (truSculpt iD, truSculpt flex, excel V+), Cutera competes in the non-invasive body contouring and skin tightening space with its truSculpt iD (RF-based fat reduction and skin tightening) and truSculpt flex (muscle stimulation) systems, directly challenging InMode's body and facial contouring solutions. They also offer laser platforms for skin and vascular treatments.
- Solta Medical (a division of Bausch Health Companies Inc.) ($BHC) (Thermage, Fraxel, Clear + Brilliant), Solta Medical is a significant competitor, particularly with its Thermage system, which is a well-established RF-based device for non-invasive skin tightening and contouring, directly competing with InMode's RF skin tightening offerings. Fraxel and Clear + Brilliant lasers compete in the skin resurfacing and rejuvenation segments.
- Alma Lasers (part of Sisram Medical Ltd.) ($1696.HK) (Accent Prime, Soprano, Harmony XL Pro), Alma Lasers offers a range of energy-based aesthetic devices. Its Accent Prime platform utilizes RF and ultrasound for body contouring and skin tightening, directly competing with InMode's body and facial remodeling technologies. Soprano (hair removal) and Harmony XL Pro (multi-application platform) also compete across various aesthetic indications.
- Merz Aesthetics (a division of Merz Pharma GmbH & Co. KGaA) (Ultherapy, Cellfina), Merz Aesthetics competes with InMode in the non-invasive lifting and tightening market through its Ultherapy system, which uses micro-focused ultrasound (MFU-V) to lift and tighten skin, offering an alternative to InMode's RF-based skin tightening solutions. Cellfina also competes in the cellulite reduction segment.
Moat:
The aesthetic medical device market is highly competitive and fragmented. InMode's primary moat lies in its proprietary, minimally-invasive radiofrequency (RF) technology, particularly its fractional RF microneedling (Morpheus8) and subdermal adipose remodeling (BodyTite/FaceTite) platforms. These technologies offer significant results with less downtime than traditional surgery, positioning InMode uniquely between non-invasive and surgical procedures. Competitors utilize various energy sources (RF, laser, ultrasound, cryolipolysis) to achieve similar aesthetic outcomes like skin tightening, fat reduction, and rejuvenation. The competition is driven by continuous innovation, clinical efficacy claims, practitioner adoption, and direct-to-consumer marketing, all vying for market share in a rapidly evolving industry.
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-11-05 | 2025-07-30 | 2025-04-28 | 2025-02-04 | 2024-12-31 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-13 | 2023-12-31 | 2023-11-02 | 2023-07-27 | 2023-05-02 | 2023-02-14 | 2022-12-31 | 2022-10-27 | 2022-07-28 | 2022-05-02 | 2022-02-10 | 2021-12-31 | 2021-10-26 | 2021-07-28 | 2021-05-05 | 2021-02-10 | 2020-12-31 | 2020-11-12 | 2020-08-05 | 2020-05-06 | 2020-02-18 | 2019-12-31 | 2019-11-05 | 2019-08-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues | 93,165,000 | 95,602,000 | 77,874,000 | 97,853,000 | 97,853,000 | 130,232,000 | 86,449,000 | 80,284,000 | 126,781,000 | 126,781,000 | 123,112,000 | 136,081,000 | 106,074,000 | 133,571,000 | 133,571,000 | 121,232,000 | 113,547,000 | 85,921,000 | 110,540,000 | 110,540,000 | 94,176,000 | 87,325,000 | 65,524,000 | 75,187,000 | 75,187,000 | 59,714,000 | 30,765,000 | 40,441,000 | 47,002,000 | -109,203,000 | 40,010,000 | 38,797,000 |
yoy | -4.79% | -26.59% | -9.92% | 21.88% | -22.82% | 2.72% | -29.78% | -41.00% | 19.52% | -5.08% | -7.83% | 12.25% | -6.58% | 55.46% | 20.83% | 9.67% | 20.57% | -1.61% | 68.70% | 47.02% | 25.26% | 46.24% | 112.98% | 85.92% | 59.97% | -154.68% | -23.11% | 4.24% | ||||
qoq | -2.55% | 22.76% | -20.42% | 0.00% | -24.86% | 50.65% | 7.68% | -36.68% | 0.00% | 2.98% | -9.53% | 28.29% | -20.59% | 0.00% | 10.18% | 6.77% | 32.15% | -22.27% | 0.00% | 17.38% | 7.85% | 33.27% | -12.85% | 0.00% | 25.91% | 94.10% | -23.93% | -13.96% | -143.04% | -372.94% | 3.13% | |
cost of revenues | 20,856,000 | 19,152,000 | 16,963,000 | 20,216,000 | 20,216,000 | 24,055,000 | 17,116,000 | 16,365,000 | 20,264,000 | 20,264,000 | 20,136,000 | 22,054,000 | 18,254,000 | 21,002,000 | 21,002,000 | 18,765,000 | 18,946,000 | 14,772,000 | 16,847,000 | 16,847,000 | 13,943,000 | 12,723,000 | 10,079,000 | 10,575,000 | 10,575,000 | 9,395,000 | 4,695,000 | 6,184,000 | 6,045,000 | 6,045,000 | 5,047,000 | 4,875,000 |
gross profit | 72,309,000 | 76,450,000 | 60,911,000 | 77,637,000 | 77,637,000 | 106,177,000 | 69,333,000 | 63,919,000 | 106,517,000 | 106,517,000 | 102,976,000 | 114,027,000 | 87,820,000 | 112,569,000 | 112,569,000 | 102,467,000 | 94,601,000 | 71,149,000 | 93,693,000 | 93,693,000 | 80,233,000 | 74,602,000 | 55,445,000 | 64,612,000 | 64,612,000 | 50,319,000 | 26,070,000 | 34,257,000 | 40,957,000 | 40,957,000 | 34,963,000 | 33,922,000 |
yoy | -6.86% | -28.00% | -12.15% | 21.46% | -27.11% | -0.32% | -32.67% | -43.94% | 21.29% | -5.38% | -8.52% | 11.28% | -7.17% | 58.22% | 20.15% | 9.36% | 17.91% | -4.63% | 68.98% | 45.01% | 24.18% | 48.26% | 112.68% | 88.61% | 57.76% | 22.86% | -25.44% | 0.99% | ||||
qoq | -5.42% | 25.51% | -21.54% | 0.00% | -26.88% | 53.14% | 8.47% | -39.99% | 0.00% | 3.44% | -9.69% | 29.84% | -21.99% | 0.00% | 9.86% | 8.31% | 32.96% | -24.06% | 0.00% | 16.78% | 7.55% | 34.55% | -14.19% | 0.00% | 28.40% | 93.01% | -23.90% | -16.36% | 0.00% | 17.14% | 3.07% | |
gross margin % | 77.61% | 79.97% | 78.22% | 79.34% | 79.34% | 81.53% | 80.20% | 79.62% | 84.02% | 84.02% | 83.64% | 83.79% | 82.79% | 84.28% | 84.28% | 84.52% | 83.31% | 82.81% | 84.76% | 84.76% | 85.19% | 85.43% | 84.62% | 85.94% | 85.94% | 84.27% | 84.74% | 84.71% | 87.14% | -37.51% | 87.39% | 87.43% |
operating expenses: | ||||||||||||||||||||||||||||||||
research and development | 3,543,000 | 3,372,000 | 2,895,000 | 2,667,000 | 2,667,000 | 3,254,000 | 3,698,000 | 3,518,000 | 3,473,000 | 3,473,000 | 3,268,000 | 3,567,000 | 3,102,000 | 3,261,000 | 3,261,000 | 3,166,000 | 3,183,000 | 2,815,000 | 2,528,000 | 2,528,000 | 2,248,000 | 2,455,000 | 2,301,000 | 2,260,000 | 2,260,000 | 1,959,000 | 1,816,000 | 3,432,000 | 1,587,000 | 1,587,000 | 1,329,000 | 1,584,000 |
sales and marketing | 44,970,000 | 47,474,000 | 39,727,000 | 44,653,000 | 44,653,000 | 51,863,000 | 45,055,000 | 39,795,000 | 49,451,000 | 49,451,000 | 50,819,000 | 51,059,000 | 41,713,000 | 47,012,000 | 47,012,000 | 43,062,000 | 39,653,000 | 30,849,000 | 35,286,000 | 35,286,000 | 30,835,000 | 28,670,000 | 24,562,000 | 25,239,000 | 25,239,000 | 23,758,000 | 14,536,000 | 22,999,000 | 20,127,000 | 20,127,000 | 16,726,000 | 15,898,000 |
general and administrative | 2,899,000 | 2,723,000 | 2,671,000 | 2,453,000 | 2,453,000 | 2,799,000 | 2,266,000 | 2,514,000 | 2,349,000 | 2,349,000 | 2,479,000 | 2,392,000 | 2,008,000 | 2,398,000 | 2,398,000 | 2,494,000 | 2,562,000 | 2,477,000 | 2,527,000 | 2,527,000 | 2,132,000 | 1,941,000 | 1,811,000 | 1,673,000 | 1,673,000 | 1,309,000 | 1,613,000 | 1,823,000 | 1,265,000 | 1,265,000 | 927,000 | 713,000 |
total operating expenses | 51,412,000 | 53,569,000 | 45,293,000 | 49,773,000 | 49,773,000 | 57,916,000 | 51,019,000 | 45,827,000 | 55,273,000 | 55,273,000 | 56,566,000 | 57,018,000 | 46,823,000 | 52,671,000 | 52,671,000 | 48,722,000 | 45,398,000 | 36,141,000 | 39,541,000 | 39,541,000 | 35,215,000 | 33,066,000 | 28,674,000 | 29,172,000 | 29,172,000 | 27,026,000 | 17,965,000 | 28,254,000 | 22,979,000 | 22,979,000 | 18,982,000 | 18,195,000 |
operations income | 20,897,000 | 22,881,000 | 15,618,000 | 27,864,000 | 21,166,750 | 48,261,000 | 18,314,000 | 18,092,000 | 51,244,000 | 36,104,000 | 46,410,000 | 57,009,000 | 40,997,000 | 59,898,000 | 59,898,000 | 53,745,000 | 49,203,000 | 35,008,000 | 54,152,000 | 54,152,000 | 45,018,000 | 41,536,000 | 26,771,000 | 35,440,000 | 35,440,000 | 23,293,000 | 8,105,000 | 6,003,000 | 17,978,000 | 17,978,000 | 15,981,000 | 15,727,000 |
yoy | -1.27% | -52.59% | -14.72% | 54.01% | -58.69% | 33.67% | -60.54% | -68.26% | 24.99% | -39.72% | -22.52% | 6.07% | -16.68% | 71.10% | 10.61% | -0.75% | 9.30% | -15.72% | 102.28% | 52.80% | 27.03% | 78.32% | 230.30% | 490.37% | 97.13% | 29.56% | -49.28% | -61.83% | ||||
qoq | -8.67% | 46.50% | -43.95% | 31.64% | -56.14% | 163.52% | 1.23% | -64.69% | 41.93% | -22.21% | -18.59% | 39.06% | -31.56% | 0.00% | 11.45% | 9.23% | 40.55% | -35.35% | 0.00% | 20.29% | 8.38% | 55.15% | -24.46% | 0.00% | 52.15% | 187.39% | 35.02% | -66.61% | 0.00% | 12.50% | 1.62% | |
operating margin % | 22.43% | 23.93% | 20.06% | 28.48% | 21.63% | 37.06% | 21.18% | 22.54% | 40.42% | 28.48% | 37.70% | 41.89% | 38.65% | 44.84% | 44.84% | 44.33% | 43.33% | 40.74% | 48.99% | 48.99% | 47.80% | 47.56% | 40.86% | 47.14% | 47.14% | 39.01% | 26.34% | 14.84% | 38.25% | -16.46% | 39.94% | 40.54% |
finance income | 4,721,000 | 8,062,000 | 6,859,000 | 4,346,000 | 4,346,000 | 9,918,000 | 8,690,000 | 7,984,000 | 8,920,000 | 8,920,000 | 4,953,000 | 4,445,000 | 3,289,000 | 3,962,000 | -918,000 | 379,000 | 118,000 | 428,000 | 44,000 | 1,228,000 | 1,228,000 | 798,000 | 636,000 | 629,000 | 1,159,000 | 479,000 | 382,000 | |||||
income before income taxes | 25,618,000 | 30,943,000 | 22,477,000 | 32,210,000 | 32,210,000 | 58,179,000 | 27,004,000 | 26,076,000 | ||||||||||||||||||||||||
income taxes | 3,755,000 | 4,201,000 | 4,276,000 | 3,188,750 | 7,189,000 | 3,186,000 | 2,380,000 | 4,999,000 | 4,999,000 | 4,843,000 | 5,725,000 | 3,781,000 | 26,152,000 | 26,152,000 | 5,145,000 | 4,237,000 | 4,412,000 | 1,585,000 | 1,585,000 | 235,000 | 1,039,000 | 69,000 | 598,000 | 598,000 | 207,000 | 161,000 | 141,000 | 165,000 | ||||
net income | 21,863,000 | 26,742,000 | 18,201,000 | 82,771,000 | 82,771,000 | 50,990,000 | 23,818,000 | 23,696,000 | 55,165,000 | 55,165,000 | 46,520,000 | 55,729,000 | 40,505,000 | 37,708,000 | 37,708,000 | 48,789,000 | 44,048,000 | 30,975,000 | 52,685,000 | 52,685,000 | 44,718,000 | 40,925,000 | 26,746,000 | 36,070,000 | 36,070,000 | 23,884,000 | 8,580,000 | 6,491,000 | 18,972,000 | 18,972,000 | 16,193,000 | 15,835,000 |
yoy | -73.59% | -47.55% | -23.58% | 249.30% | 50.04% | -7.57% | -48.80% | -57.48% | 36.19% | 46.30% | 23.37% | 14.22% | -8.04% | 21.74% | -28.43% | -7.39% | -1.50% | -24.31% | 96.98% | 46.06% | 23.98% | 71.35% | 211.72% | 455.69% | 90.12% | 25.89% | -47.01% | -59.01% | ||||
qoq | -18.24% | 46.93% | -78.01% | 0.00% | 62.33% | 114.08% | 0.51% | -57.05% | 0.00% | 18.58% | -16.52% | 37.59% | 7.42% | 0.00% | -22.71% | 10.76% | 42.21% | -41.21% | 0.00% | 17.82% | 9.27% | 53.01% | -25.85% | 0.00% | 51.02% | 178.37% | 32.18% | -65.79% | 0.00% | 17.16% | 2.26% | |
net income margin % | 23.47% | 27.97% | 23.37% | 84.59% | 84.59% | 39.15% | 27.55% | 29.52% | 43.51% | 43.51% | 37.79% | 40.95% | 38.19% | 28.23% | 28.23% | 40.24% | 38.79% | 36.05% | 47.66% | 47.66% | 47.48% | 46.87% | 40.82% | 47.97% | 47.97% | 40.00% | 27.89% | 16.05% | 40.36% | -17.37% | 40.47% | 40.82% |
earnings per share: | ||||||||||||||||||||||||||||||||
basic | 0.35 | 0.42 | 0.26 | 1.15 | 1.09 | 0.66 | 0.28 | 0.28 | ||||||||||||||||||||||||
diluted | 0.34 | 0.42 | 0.26 | 1.14 | 1.06 | 0.65 | 0.28 | 0.28 | ||||||||||||||||||||||||
weighted-average number of shares outstanding used in computation of earnings per share | ||||||||||||||||||||||||||||||||
basic | 63,291 | 63,252 | 68,760 | 71,874 | 79,306,371 | 77,022 | 83,878 | 84,523 | 83,862 | 83,533,593 | 83,703 | 83,405 | 83,154 | 82,449 | 82,482,090 | 82,306 | 82,216 | 82,973 | 83,234 | 81,444,938 | 82,705 | 40,850 | 39,029 | 37,593 | 36,057,182 | 36,697 | 35,943 | 33,963 | 32,781 | 29,231,476 | 30,297 | 26,963 |
diluted | 63,868 | 63,637 | 69,435 | 72,787 | 80,596,682 | 77,908 | 85,890 | 85,965 | 85,835 | 85,953,581 | 85,970 | 85,650 | 85,387 | 85,288 | 85,403,714 | 84,823 | 84,663 | 85,696 | 86,384 | 86,017,203 | 86,264 | 42,881 | 42,517 | 42,389 | 42,092,299 | 42,082 | 41,733 | 41,688 | 41,639 | 38,058,625 | 39,004 | 35,344 |
income taxes benefit | 50,561,000 | |||||||||||||||||||||||||||||||
income before taxes | 60,164,000 | 39,275,750 | 51,363,000 | 61,454,000 | 44,286,000 | 63,860,000 | 63,860,000 | 53,934,000 | 48,285,000 | 35,387,000 | 54,270,000 | 54,270,000 | 44,953,000 | 41,964,000 | 26,815,000 | 36,668,000 | 36,668,000 | 24,091,000 | 8,741,000 | 6,632,000 | 19,137,000 | 19,137,000 | 16,460,000 | 16,109,000 | ||||||||
net income per share | ||||||||||||||||||||||||||||||||
basic | 0.66 | 0.428 | 0.56 | 0.67 | 0.49 | 0.46 | 0.46 | 0.59 | 0.54 | 0.37 | 0.63 | 0.64 | 0.54 | 1 | 0.68 | 0.96 | 0.99 | 0.65 | 0.24 | 0.19 | 0.58 | 0.59 | 0.53 | 0.58 | ||||||||
diluted | 0.64 | 0.415 | 0.54 | 0.65 | 0.47 | 0.44 | 0.44 | 0.58 | 0.52 | 0.36 | 0.61 | 0.61 | 0.52 | 0.95 | 0.63 | 0.85 | 0.85 | 0.57 | 0.21 | 0.15 | 0.46 | 0.45 | 0.42 | 0.45 | ||||||||
weighted-average number of shares outstanding used in computation of net income per share | ||||||||||||||||||||||||||||||||
basic | 63,291 | 63,252 | 68,760 | 71,874 | 79,306,371 | 77,022 | 83,878 | 84,523 | 83,862 | 83,533,593 | 83,703 | 83,405 | 83,154 | 82,449 | 82,482,090 | 82,306 | 82,216 | 82,973 | 83,234 | 81,444,938 | 82,705 | 40,850 | 39,029 | 37,593 | 36,057,182 | 36,697 | 35,943 | 33,963 | 32,781 | 29,231,476 | 30,297 | 26,963 |
diluted | 63,868 | 63,637 | 69,435 | 72,787 | 80,596,682 | 77,908 | 85,890 | 85,965 | 85,835 | 85,953,581 | 85,970 | 85,650 | 85,387 | 85,288 | 85,403,714 | 84,823 | 84,663 | 85,696 | 86,384 | 86,017,203 | 86,264 | 42,881 | 42,517 | 42,389 | 42,092,299 | 42,082 | 41,733 | 41,688 | 41,639 | 38,058,625 | 39,004 | 35,344 |
other income | -800,000 | |||||||||||||||||||||||||||||||
less: net income attributable to non-controlling interests | 58,000 | -66,000 | -66,000 | 7,000 | -38,000 | |||||||||||||||||||||||||||
net income attributable to inmode ltd. | 37,708,000 | 30,953,000 | 48,789,000 | 44,048,000 | 30,975,000 | 52,685,000 | 28,071,500 | 44,718,000 | 40,925,000 | 26,643,000 | 36,114,000 | 9,729,000 | 23,895,000 | 8,588,000 | 6,433,000 | 19,038,000 | ||||||||||||||||
finance income (expenses) | -87,500 | 189,000 | 101,750 | -65,000 | 1,159,000 | |||||||||||||||||||||||||||
add: net income attributable to non-controlling interests | -103,000 | |||||||||||||||||||||||||||||||
add: loss (net income) attributable to non-controlling interests | 44,000 | 44,000 | 11,000 | 8,000 | ||||||||||||||||||||||||||||
legal settlements and loss contingencies | ||||||||||||||||||||||||||||||||
income tax | 179,500 | 267,000 | 274,000 | |||||||||||||||||||||||||||||
net income attributable to inmode ltd. shareholders’ | 10,526,750 | 16,186,000 | 15,797,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-11-05 | 2025-09-30 | 2025-07-30 | 2025-06-30 | 2025-04-28 | 2025-03-31 | 2025-02-04 | 2024-12-31 | 2024-10-30 | 2024-09-30 | 2024-08-01 | 2024-06-30 | 2024-05-02 | 2024-03-31 | 2024-02-13 | 2023-12-31 | 2023-11-02 | 2023-09-30 | 2023-07-27 | 2023-06-30 | 2023-05-02 | 2023-03-31 | 2023-02-14 | 2022-12-31 | 2022-10-27 | 2022-09-30 | 2022-07-28 | 2022-06-30 | 2022-05-02 | 2022-03-31 | 2022-02-10 | 2021-12-31 | 2021-10-26 | 2021-09-30 | 2021-07-28 | 2021-06-30 | 2021-05-05 | 2021-03-31 | 2021-02-10 | 2020-12-31 | 2020-11-12 | 2020-08-05 | 2020-06-30 | 2020-05-06 | 2020-03-31 | 2020-02-18 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 252,437,000 | 252,437,000 | 216,237,000 | 216,237,000 | 145,948,000 | 145,948,000 | 155,329,000 | 155,329,000 | 164,838,000 | 164,838,000 | 91,997,000 | 91,997,000 | 120,930,000 | 120,930,000 | 144,411,000 | 144,411,000 | 133,733,000 | 133,733,000 | 159,855,000 | 159,855,000 | 92,961,000 | 92,961,000 | 97,540,000 | 97,540,000 | 77,048,000 | 77,048,000 | 88,404,000 | 88,404,000 | 44,670,000 | 44,670,000 | 68,136,000 | 68,136,000 | 68,928,000 | 68,928,000 | 61,772,000 | 61,772,000 | 64,901,000 | 64,901,000 | 68,938,000 | 68,938,000 | 68,835,000 | 64,767,000 | 64,767,000 | 45,138,000 | 45,138,000 | 44,727,000 | 44,727,000 | 48,705,000 | 28,877,000 |
marketable securities | 121,518,000 | 121,518,000 | 183,388,000 | 183,388,000 | 224,457,000 | 224,457,000 | 267,688,000 | 267,688,000 | 281,458,000 | 281,458,000 | 333,517,000 | 333,517,000 | 390,782,000 | 390,782,000 | 373,647,000 | 373,647,000 | 385,860,000 | 385,860,000 | 400,464,000 | 400,464,000 | 405,674,000 | 405,674,000 | 374,589,000 | 374,589,000 | 334,934,000 | 334,934,000 | 299,322,000 | 299,322,000 | 298,400,000 | 298,400,000 | 294,530,000 | 294,530,000 | 265,262,000 | 265,262,000 | 218,845,000 | 218,845,000 | 177,081,000 | 177,081,000 | 142,007,000 | 142,007,000 | 122,046,000 | 106,668,000 | 106,668,000 | 126,101,000 | 126,101,000 | 120,144,000 | 120,144,000 | 91,613,000 | 36,677,000 |
short-term bank deposits | 158,353,000 | 158,353,000 | 111,058,000 | 111,058,000 | 142,520,000 | 142,520,000 | 173,455,000 | 173,455,000 | 238,592,000 | 238,592,000 | 303,694,000 | 303,694,000 | 258,829,000 | 258,829,000 | 223,547,000 | 223,547,000 | 156,253,000 | 156,253,000 | 69,094,000 | 69,094,000 | 75,817,000 | 75,817,000 | 75,254,000 | 75,254,000 | 74,405,000 | 74,405,000 | 55,913,000 | 55,913,000 | 56,392,000 | 56,392,000 | 53,248,000 | 53,248,000 | 53,221,000 | 53,221,000 | 52,261,000 | 52,261,000 | 51,441,000 | 51,441,000 | 49,589,000 | 49,589,000 | 43,436,000 | 31,971,000 | 31,971,000 | 30,470,000 | 30,470,000 | 28,491,000 | 28,491,000 | 25,935,000 | 17,220,000 |
accounts receivable | 38,095,000 | 38,095,000 | 35,654,000 | 35,654,000 | 32,367,000 | 32,367,000 | 36,335,000 | 36,335,000 | 40,777,000 | 40,777,000 | 38,154,000 | 38,154,000 | 33,102,000 | 33,102,000 | 42,362,000 | 42,362,000 | 42,692,000 | 42,692,000 | 32,568,000 | 32,568,000 | 24,868,000 | 24,868,000 | 26,997,000 | 26,997,000 | 28,056,000 | 28,056,000 | 21,261,000 | 21,261,000 | 16,104,000 | 16,104,000 | 20,236,000 | 20,236,000 | 22,629,000 | 22,629,000 | 18,250,000 | 18,250,000 | 15,044,000 | 15,044,000 | 10,499,000 | 10,499,000 | 16,164,000 | 8,608,000 | 8,608,000 | 5,769,000 | 5,769,000 | 6,628,000 | 6,628,000 | 7,615,000 | 5,238,000 |
prepaid expense and other receivables | 24,485,000 | 24,485,000 | 24,334,000 | 24,334,000 | 25,564,000 | 25,564,000 | 22,097,000 | 22,097,000 | 24,447,000 | 24,447,000 | 23,003,000 | 23,003,000 | 18,939,000 | 18,939,000 | 16,268,000 | 15,094,000 | |||||||||||||||||||||||||||||||||
inventories | 71,403,000 | 71,403,000 | 68,110,000 | 68,110,000 | 63,781,000 | 63,781,000 | 59,548,000 | 59,548,000 | 58,284,000 | 58,284,000 | 52,627,000 | 52,627,000 | 51,602,000 | 51,602,000 | 45,095,000 | 45,095,000 | 39,989,000 | 39,989,000 | 38,568,000 | 38,568,000 | 40,811,000 | 40,811,000 | 39,897,000 | 39,897,000 | 35,810,000 | 35,810,000 | 29,760,000 | 29,760,000 | 25,100,000 | 25,100,000 | 21,026,000 | 21,026,000 | 19,178,000 | 19,178,000 | 17,394,000 | 17,394,000 | 15,700,000 | 15,700,000 | 14,983,000 | 14,983,000 | 14,871,000 | 16,227,000 | 16,227,000 | 12,086,000 | 12,086,000 | 9,408,000 | 9,408,000 | 8,495,000 | 7,616,000 |
total current assets | 666,291,000 | 666,291,000 | 638,781,000 | 638,781,000 | 634,637,000 | 634,637,000 | 714,452,000 | 714,452,000 | 808,396,000 | 808,396,000 | 842,992,000 | 842,992,000 | 874,184,000 | 874,184,000 | 845,330,000 | 845,330,000 | 777,912,000 | 777,912,000 | 719,205,000 | 719,205,000 | 654,933,000 | 654,933,000 | 629,371,000 | 629,371,000 | 563,983,000 | 563,983,000 | 509,208,000 | 509,208,000 | 454,848,000 | 454,848,000 | 470,114,000 | 439,988,000 | 439,988,000 | 375,344,000 | 375,344,000 | 332,026,000 | 332,026,000 | 289,591,000 | 270,142,000 | 233,568,000 | 233,568,000 | 224,974,000 | 224,974,000 | 213,208,000 | 185,505,000 | 96,954,000 | |||
non-current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||
deferred income tax asset | 54,104,000 | 54,104,000 | 54,763,000 | 54,763,000 | 55,338,000 | 55,338,000 | 56,285,000 | 1,048,000 | 1,048,000 | 1,402,000 | 1,402,000 | 1,494,000 | 1,494,000 | 1,506,000 | 2,103,000 | 2,103,000 | 2,350,000 | 2,350,000 | 2,457,000 | 2,457,000 | 3,094,000 | ||||||||||||||||||||||||||||
operating lease right-of-use assets | 8,922,000 | 8,922,000 | 9,299,000 | 9,299,000 | 9,133,000 | 9,133,000 | 8,732,000 | 8,732,000 | 8,636,000 | 8,636,000 | 9,246,000 | 9,246,000 | 9,593,000 | 9,593,000 | 9,698,000 | 9,698,000 | 6,359,000 | 6,359,000 | 5,595,000 | 5,595,000 | 5,288,000 | 5,288,000 | 5,073,000 | 5,073,000 | 5,191,000 | 5,191,000 | 5,004,000 | 5,004,000 | 4,130,000 | 4,130,000 | 4,321,000 | 4,321,000 | 4,652,000 | 4,652,000 | 4,988,000 | 4,988,000 | 2,949,000 | 2,949,000 | 1,153,000 | 1,153,000 | 1,282,000 | 1,413,000 | 1,413,000 | 1,480,000 | 1,480,000 | 1,369,000 | 1,369,000 | 1,518,000 | 1,609,000 |
property and equipment | 2,238,000 | 2,238,000 | 2,260,000 | 2,260,000 | 2,233,000 | 2,233,000 | 2,322,000 | 2,322,000 | 2,336,000 | 2,336,000 | 2,396,000 | 2,396,000 | 2,329,000 | 2,329,000 | 2,382,000 | 2,382,000 | 2,482,000 | 2,482,000 | 2,463,000 | 2,463,000 | 2,451,000 | 2,451,000 | 2,298,000 | 2,298,000 | 2,189,000 | 2,189,000 | 1,971,000 | 1,971,000 | 1,565,000 | 1,565,000 | 1,404,000 | 1,404,000 | 1,361,000 | 1,361,000 | 1,243,000 | 1,243,000 | 1,033,000 | 1,033,000 | 982,000 | 982,000 | 1,056,000 | 1,061,000 | 1,061,000 | 940,000 | 940,000 | 935,000 | 935,000 | 848,000 | 871,000 |
other investments | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | ||
total non-current assets | 68,314,000 | 68,314,000 | 69,567,000 | 69,567,000 | 70,098,000 | 70,098,000 | 71,215,000 | 71,215,000 | 15,637,000 | 15,637,000 | 16,844,000 | 16,844,000 | 17,551,000 | 17,551,000 | 17,956,000 | 17,956,000 | 15,618,000 | 15,618,000 | 14,879,000 | 14,879,000 | 14,679,000 | 14,679,000 | 15,038,000 | 15,038,000 | 15,001,000 | 15,001,000 | 13,997,000 | 13,997,000 | 9,618,000 | 9,618,000 | 8,427,000 | 7,670,000 | 7,670,000 | 7,687,000 | 7,687,000 | 5,266,000 | 5,266,000 | 6,170,000 | 3,999,000 | 4,450,000 | 4,450,000 | 4,727,000 | 4,727,000 | 5,177,000 | 4,260,000 | 5,603,000 | |||
total assets | 734,605,000 | 734,605,000 | 708,348,000 | 708,348,000 | 704,735,000 | 704,735,000 | 785,667,000 | 785,667,000 | 824,033,000 | 824,033,000 | 859,836,000 | 859,836,000 | 891,735,000 | 891,735,000 | 863,286,000 | 863,286,000 | 793,530,000 | 793,530,000 | 734,084,000 | 734,084,000 | 669,612,000 | 669,612,000 | 644,409,000 | 644,409,000 | 578,984,000 | 578,984,000 | 523,205,000 | 523,205,000 | 464,466,000 | 464,466,000 | 478,541,000 | 447,658,000 | 447,658,000 | 383,031,000 | 383,031,000 | 337,292,000 | 337,292,000 | 295,761,000 | 274,141,000 | 238,018,000 | 238,018,000 | 229,701,000 | 229,701,000 | 218,385,000 | 189,765,000 | 102,557,000 | |||
liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 16,723,000 | 16,723,000 | 17,482,000 | 17,482,000 | 15,052,000 | 15,052,000 | 13,782,000 | 13,782,000 | 14,313,000 | 14,313,000 | 15,548,000 | 15,548,000 | 13,223,000 | 13,223,000 | 13,966,000 | 13,966,000 | 12,333,000 | 12,333,000 | 13,295,000 | 13,295,000 | 11,987,000 | 11,987,000 | 16,242,000 | 16,242,000 | 13,296,000 | 13,296,000 | 11,833,000 | 11,833,000 | 9,541,000 | 9,541,000 | 8,779,000 | 8,779,000 | 8,884,000 | 8,884,000 | 7,723,000 | 7,723,000 | 7,410,000 | 7,410,000 | 6,410,000 | 6,410,000 | 4,283,000 | 4,026,000 | 4,026,000 | 4,716,000 | 4,716,000 | 3,702,000 | 3,702,000 | 5,660,000 | 4,867,000 |
contract liabilities | 15,099,000 | 15,099,000 | 12,996,000 | 12,996,000 | 15,861,000 | 15,861,000 | 16,755,000 | 16,755,000 | 17,230,000 | 17,230,000 | 43,610,000 | 43,610,000 | 20,516,000 | 20,516,000 | 10,923,000 | 10,923,000 | 10,625,000 | 10,625,000 | 11,098,000 | 11,098,000 | 17,293,000 | 17,293,000 | 13,798,000 | 13,798,000 | 12,450,000 | 12,450,000 | 18,102,000 | 18,102,000 | 16,330,000 | 16,330,000 | 13,805,000 | 13,805,000 | 12,804,000 | 12,804,000 | 13,332,000 | 13,332,000 | 13,273,000 | 13,273,000 | 11,900,000 | 11,900,000 | 15,671,000 | 10,283,000 | 10,283,000 | 13,249,000 | 13,249,000 | 15,587,000 | 15,587,000 | 7,260,000 | 8,276,000 |
other liabilities | 36,508,000 | 36,508,000 | 36,056,000 | 36,056,000 | 41,745,000 | 41,745,000 | 39,314,000 | 39,314,000 | 44,155,000 | 44,155,000 | 38,532,000 | 38,532,000 | 31,256,000 | 31,256,000 | 39,247,000 | 39,247,000 | 39,230,000 | 39,230,000 | 36,340,000 | 36,340,000 | 30,391,000 | 30,391,000 | 51,980,000 | 51,980,000 | 32,181,000 | 32,181,000 | 28,054,000 | 28,054,000 | 23,947,000 | 23,947,000 | 29,266,000 | 29,266,000 | 32,183,000 | 32,183,000 | 21,116,000 | 21,116,000 | 15,993,000 | 15,993,000 | 16,720,000 | 16,720,000 | 17,572,000 | 13,503,000 | 13,503,000 | 11,309,000 | 11,309,000 | 13,205,000 | 13,205,000 | 10,783,000 | 9,802,000 |
total current liabilities | 68,330,000 | 68,330,000 | 66,534,000 | 66,534,000 | 72,658,000 | 72,658,000 | 69,851,000 | 69,851,000 | 75,698,000 | 75,698,000 | 97,690,000 | 97,690,000 | 64,995,000 | 64,995,000 | 64,136,000 | 64,136,000 | 62,188,000 | 62,188,000 | 60,733,000 | 60,733,000 | 59,671,000 | 59,671,000 | 82,020,000 | 82,020,000 | 57,927,000 | 57,927,000 | 57,989,000 | 57,989,000 | 49,818,000 | 49,818,000 | 51,850,000 | 53,871,000 | 53,871,000 | 42,171,000 | 42,171,000 | 36,676,000 | 36,676,000 | 35,030,000 | 37,526,000 | 27,812,000 | 27,812,000 | 29,274,000 | 29,274,000 | 32,494,000 | 23,703,000 | 22,945,000 | |||
non-current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||
operating lease liabilities | 5,593,000 | 5,593,000 | 6,103,000 | 6,103,000 | 5,588,000 | 5,588,000 | 5,311,000 | 5,311,000 | 5,317,000 | 5,317,000 | 5,671,000 | 5,671,000 | 6,213,000 | 6,213,000 | 6,613,000 | 6,613,000 | 3,581,000 | 3,581,000 | 3,622,000 | 3,622,000 | 3,529,000 | 3,529,000 | 3,509,000 | 3,509,000 | 3,657,000 | 3,657,000 | 3,678,000 | 3,678,000 | 3,079,000 | 3,079,000 | 3,307,000 | 3,307,000 | 3,546,000 | 3,546,000 | 3,764,000 | 3,764,000 | 1,976,000 | 1,976,000 | 358,000 | 358,000 | 519,000 | 660,000 | 660,000 | 709,000 | 709,000 | 744,000 | 744,000 | 922,000 | 1,021,000 |
total non-current liabilities | 12,890,000 | 12,890,000 | 13,377,000 | 13,377,000 | 12,649,000 | 12,649,000 | 12,003,000 | 12,003,000 | 11,443,000 | 11,443,000 | 11,025,000 | 11,025,000 | 11,305,000 | 11,305,000 | 11,778,000 | 11,778,000 | 7,845,000 | 7,845,000 | 7,193,000 | 7,193,000 | 6,962,000 | 6,962,000 | 7,771,000 | 7,771,000 | 12,754,000 | 12,754,000 | 12,402,000 | 12,402,000 | 11,330,000 | 11,330,000 | 10,889,000 | 9,761,000 | 9,761,000 | 9,684,000 | 9,684,000 | 6,869,000 | 6,869,000 | 5,256,000 | 4,589,000 | 5,050,000 | 5,050,000 | 5,594,000 | 5,594,000 | 6,088,000 | 5,627,000 | 5,688,000 | |||
total liabilities | 81,220,000 | 81,220,000 | 79,911,000 | 79,911,000 | 85,307,000 | 85,307,000 | 81,854,000 | 81,854,000 | 87,141,000 | 87,141,000 | 108,715,000 | 108,715,000 | 76,300,000 | 76,300,000 | 75,914,000 | 75,914,000 | 70,033,000 | 70,033,000 | 67,926,000 | 67,926,000 | 66,633,000 | 66,633,000 | 89,791,000 | 89,791,000 | 70,681,000 | 70,681,000 | 70,391,000 | 70,391,000 | 61,148,000 | 61,148,000 | 62,739,000 | 63,632,000 | 63,632,000 | 51,855,000 | 51,855,000 | 43,545,000 | 43,545,000 | 40,286,000 | 42,115,000 | 32,862,000 | 32,862,000 | 34,868,000 | 34,868,000 | 38,582,000 | 29,330,000 | 28,633,000 | |||
total shareholders’ equity | 653,385,000 | 653,385,000 | 628,437,000 | 628,437,000 | 619,428,000 | 619,428,000 | 703,813,000 | 703,813,000 | 736,892,000 | 736,892,000 | 751,121,000 | 751,121,000 | 815,435,000 | 815,435,000 | 787,372,000 | 787,372,000 | 723,497,000 | 723,497,000 | 666,158,000 | 666,158,000 | 602,979,000 | 602,979,000 | 554,618,000 | 554,618,000 | 508,303,000 | 508,303,000 | 452,814,000 | 452,814,000 | 403,318,000 | 403,318,000 | 415,802,000 | 384,026,000 | 384,026,000 | 331,176,000 | 331,176,000 | 293,747,000 | 293,747,000 | 255,475,000 | 232,026,000 | 205,156,000 | 205,156,000 | 194,833,000 | 194,833,000 | 179,803,000 | 160,435,000 | 71,607,000 | |||
total liabilities and shareholders’ equity | 734,605,000 | 734,605,000 | 708,348,000 | 708,348,000 | 704,735,000 | 704,735,000 | 785,667,000 | 785,667,000 | 824,033,000 | 824,033,000 | 859,836,000 | 859,836,000 | 891,735,000 | 891,735,000 | 863,286,000 | 863,286,000 | 793,530,000 | 793,530,000 | 734,084,000 | 734,084,000 | 669,612,000 | 669,612,000 | 644,409,000 | 578,984,000 | 578,984,000 | 523,205,000 | 523,205,000 | 464,466,000 | 464,466,000 | 478,541,000 | 447,658,000 | 447,658,000 | 383,031,000 | 383,031,000 | 337,292,000 | 337,292,000 | 295,761,000 | 274,141,000 | 238,018,000 | 238,018,000 | 229,701,000 | 229,701,000 | 218,385,000 | 189,765,000 | 102,557,000 | ||||
accounts receivable net of allowance for credit losses of 924 and 716 as of december 31, 2024 and 2023, respectively | 3,176,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred income tax assets | 56,285,000 | 1,506,000 | 3,094,000 | ||||||||||||||||||||||||||||||||||||||||||||||
commitments and contingencies | |||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares, nis 0.01 par value... | 249,000 | 245,000 | 93,000 | ||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital | 197,028,000 | 177,820,000 | 148,803,000 | 122,698,000 | 101,701,000 | 81,863,000 | |||||||||||||||||||||||||||||||||||||||||||
retained earnings | 874,701,000 | 693,426,000 | 495,507,000 | 333,987,000 | 169,016,000 | 93,986,000 | |||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -340,000 | -1,679,000 | -7,493,000 | ||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares, at cost: 18,025,003 and 1,975,003 ordinary shares at december 31, 2024 and 2023, respectively | -367,825,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
other receivables | 16,268,000 | 19,385,000 | 19,385,000 | 18,656,000 | 18,656,000 | 14,802,000 | 14,802,000 | 15,094,000 | 13,730,000 | 13,730,000 | 14,548,000 | 14,548,000 | 14,182,000 | 14,182,000 | 12,938,000 | 12,938,000 | 10,770,000 | 10,770,000 | 6,822,000 | 6,822,000 | 7,859,000 | 7,859,000 | 3,575,000 | 3,575,000 | 4,790,000 | 5,327,000 | 5,327,000 | 5,410,000 | 5,410,000 | 3,810,000 | 3,810,000 | 3,142,000 | 1,326,000 | ||||||||||||||||
accounts receivable net of allowance for credit losses of 716 and 482 as of december 31, 2023 and 2022, respectively | 3,670,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares, at cost: 1,975,003 and 1,975,003 ordinary shares at december 31, 2023 and 2022, respectively | -82,440,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable net of allowance for credit losses of 482 and 0 at december 31, 2022 and 2021, respectively | 3,973,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable net of allowance for credit losses of 482 and 0 as of december 31, 2022 and 2021, respectively | 3,973,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
inmode ltd. shareholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||||
issued 84,519,994 and 83,875,905 shares at december 31, 2022 and 2021, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||
outstanding 82,544,991 and 82,978,115 shares at december 31, 2022 and 2021, respectively | 241,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares, at cost: 1,975,003 and 897,790 ordinary shares at december 31, 2022 and 2021, respectively | -82,440,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
tot l liabilities and shareholders’ equity | 644,409,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | 3,255,000 | 3,255,000 | 2,737,000 | 2,737,000 | 2,586,000 | 2,586,000 | 1,334,000 | 1,334,000 | 607,000 | 607,000 | 382,000 | 382,000 | 223,000 | 223,000 | 64,000 | 64,000 | 606,000 | 993,000 | 993,000 | 1,370,000 | 1,370,000 | 1,899,000 | 1,899,000 | 1,516,000 | 1,452,000 | ||||||||||||||||||||||||
t o t a l current assets | 470,114,000 | 289,591,000 | 213,208,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l non-current assets | 8,427,000 | 6,170,000 | 5,177,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l assets | 478,541,000 | 295,761,000 | 218,385,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l current liabilities | 51,850,000 | 35,030,000 | 32,494,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l non-current liabilities | 10,889,000 | 5,256,000 | 6,088,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l liabilities | 62,739,000 | 40,286,000 | 38,582,000 | ||||||||||||||||||||||||||||||||||||||||||||||
issued 83,875,905 and 76,354,436 shares at december 31, 2021 and 2020, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||
outstanding 82,978,115 and 75,567,554 shares at december 31, 2021 and 2020, respectively | 239,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income | -1,319,000 | 356,000 | 124,000 | ||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares, at cost 897,790 and 786,882 ordinary shares at december 31, 2021 and 2020, respectively | -39,803,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
inmode ltd. shareholders’ equity: - sum | 415,802,000 | 253,963,000 | 176,066,000 | ||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests | 1,512,000 | 3,737,000 | |||||||||||||||||||||||||||||||||||||||||||||||
t o t a l shareholders’ equity | 415,802,000 | 255,475,000 | 179,803,000 | ||||||||||||||||||||||||||||||||||||||||||||||
t o t a l liabilities and shareholders’ equity | 478,541,000 | 295,761,000 | 218,385,000 | ||||||||||||||||||||||||||||||||||||||||||||||
issued 38,177,218 and 32,799,082 shares at december 31, 2020 and 2019, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||
outstanding 37,783,777 and 32,799,082 shares at december 31, 2020 and 2019, respectively | 108,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares, at cost at december 31, 2020: 393,441 ordinary shares | -17,218,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred offering costs | 1,185,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accrued contingencies | |||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interest | 2,317,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||
net income | 16,193,000 | 15,835,000 | |||||||||||||||||||||||||||||||||||||||||||||||
adjustments required to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 77,000 | 74,000 | |||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation expense | 385,000 | 412,000 | |||||||||||||||||||||||||||||||||||||||||||||||
allowance for doubtful accounts | 55,000 | 19,000 | |||||||||||||||||||||||||||||||||||||||||||||||
gains on marketable securities | |||||||||||||||||||||||||||||||||||||||||||||||||
changes in fair value of marketable securities | |||||||||||||||||||||||||||||||||||||||||||||||||
finance income | -86,000 | -126,000 | |||||||||||||||||||||||||||||||||||||||||||||||
benefit from deferred income taxes | -68,000 | -77,000 | |||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable | -2,324,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
increase in other receivables | -1,814,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
decrease (increase) in inventories | -879,000 | -524,000 | |||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable | 689,000 | 1,085,000 | |||||||||||||||||||||||||||||||||||||||||||||||
increase in other liabilities | 2,402,000 | 465,000 | |||||||||||||||||||||||||||||||||||||||||||||||
increase in contract liabilities | -1,115,000 | -533,000 | |||||||||||||||||||||||||||||||||||||||||||||||
decrease in accrued contingencies | |||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities | 13,515,000 | 18,501,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cash flows from investing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||
investment in short-term deposits | -17,220,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from short-term deposits | 8,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
purchase of fixed assets | -54,000 | -86,000 | |||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities | -68,282,000 | -9,421,000 | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of marketable securities | 13,500,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net cash (used in) investing activities | -63,556,000 | -8,597,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cash flows from financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from initial public offering of ordinary shares, net of issuance costs | 69,784,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
exercise of options | 178,000 | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | 69,962,000 | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash | -93,000 | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | 19,828,000 | 9,926,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at | 28,877,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
beginning of period | |||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | 48,705,000 | 28,877,000 | |||||||||||||||||||||||||||||||||||||||||||||||
decrease in accounts receivable | 1,580,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other receivables | 291,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
investment in short-term deposit | -6,090,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from short-term deposit | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 18,951,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-04-28 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-05-02 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-05-02 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-05-02 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-05-05 | 2021-03-31 | 2020-12-31 | 2020-11-12 | 2020-06-30 | 2020-05-06 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||||||||||||||||
net income | -4,879,000 | 8,541,000 | 18,201,000 | 18,201,000 | 130,285,000 | 27,172,000 | 122,000 | 23,696,000 | 23,696,000 | 151,399,000 | -9,209,000 | 15,224,000 | 40,505,000 | 40,505,000 | 112,731,000 | 4,741,000 | 13,073,000 | 30,975,000 | 30,975,000 | 120,356,000 | 3,793,000 | 14,179,000 | 26,746,000 | 26,746,000 | 51,141,000 | 15,304,000 | 2,089,000 | 6,491,000 | 6,491,000 | 44,965,000 | 358,000 |
adjustments required to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||
depreciation and amortization | -35,000 | 17,000 | 174,000 | 174,000 | 590,000 | -39,000 | 12,000 | 165,000 | 165,000 | 494,000 | -55,000 | -4,000 | 188,000 | 188,000 | 511,000 | 14,000 | 17,000 | 138,000 | 138,000 | 381,000 | 8,000 | 14,000 | 114,000 | 114,000 | 308,000 | 3,000 | 11,000 | 94,000 | 94,000 | 225,000 | 3,000 |
share-based compensation expenses | -722,000 | 900,000 | 2,518,000 | 2,518,000 | 12,588,000 | -1,177,000 | 1,175,000 | 3,983,000 | 3,983,000 | 17,036,000 | 59,000 | 2,296,000 | 4,209,000 | 4,209,000 | 16,595,000 | 1,504,000 | 3,259,000 | 3,094,000 | 3,094,000 | 8,770,000 | 244,000 | 250,000 | 2,698,000 | 2,698,000 | 10,441,000 | 1,244,000 | -4,890,000 | 6,050,000 | 6,050,000 | ||
change in allowance for credit losses of trade receivable | -41,000 | 241,000 | -94,000 | -94,000 | 442,000 | 33,000 | -90,000 | 187,000 | 187,000 | -22,000 | -22,000 | ||||||||||||||||||||
loss on marketable securities | 6,000 | 138,000 | -83,000 | 83,000 | 29,000 | 29,000 | 59,000 | -11,000 | 9,000 | 14,000 | 14,000 | 149,000 | |||||||||||||||||||
finance expenses (income) | 670,000 | 315,000 | -1,512,000 | -1,512,000 | -110,000 | 189,000 | 189,000 | ||||||||||||||||||||||||
deferred income taxes | 36,000 | -330,000 | 896,000 | 896,000 | 91,000 | -19,000 | -37,000 | -37,000 | -259,000 | 24,000 | 19,000 | 19,000 | -160,000 | 191,000 | -22,000 | -22,000 | -581,000 | -88,000 | 0 | -101,000 | -101,000 | 1,382,000 | -111,000 | 90,000 | 368,000 | 368,000 | |||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||
decrease in accounts receivable | 4,544,000 | 4,544,000 | 8,519,000 | 9,308,000 | 9,308,000 | 2,241,000 | 2,241,000 | 3,953,000 | -4,569,000 | 590,000 | 590,000 | ||||||||||||||||||||
increase in other receivables | -3,532,000 | -3,532,000 | -4,838,000 | 3,188,000 | -1,379,000 | -2,669,000 | -2,669,000 | -3,562,000 | -229,000 | -229,000 | -1,195,000 | -1,195,000 | -1,380,000 | -1,380,000 | 498,000 | ||||||||||||||||
increase in inventories | 1,036,000 | -96,000 | -4,233,000 | -4,233,000 | -8,796,000 | -6,507,000 | -6,507,000 | -3,777,000 | -914,000 | -914,000 | -12,821,000 | -1,390,000 | -586,000 | -4,074,000 | -4,074,000 | -977,000 | -717,000 | -717,000 | -1,463,000 | -2,678,000 | -2,678,000 | ||||||||||
increase in accounts payable | -3,189,000 | 1,160,000 | 1,270,000 | 1,270,000 | 1,051,000 | -3,560,000 | -1,314,000 | -2,270,000 | 5,563,000 | -4,255,000 | -4,255,000 | 6,000,000 | -829,000 | 1,530,000 | 762,000 | 762,000 | 1,208,000 | 848,000 | -687,000 | 1,000,000 | 1,000,000 | 2,451,000 | 947,000 | -1,704,000 | 1,014,000 | 1,014,000 | -597,000 | ||||
increase in other liabilities | 437,000 | -9,805,000 | 9,481,000 | -15,628,000 | -4,171,000 | 13,805,000 | 31,000 | 2,981,000 | 5,325,000 | 643,000 | 1,864,000 | 1,692,000 | |||||||||||||||||||
increase in contract liabilities | 4,777,000 | -2,066,000 | -837,000 | -837,000 | 31,919,000 | -49,631,000 | 13,852,000 | 9,262,000 | 9,262,000 | -11,473,000 | 3,926,000 | 3,926,000 | 6,591,000 | -7,538,000 | -635,000 | 2,783,000 | 2,783,000 | 2,945,000 | -428,000 | -1,170,000 | 1,321,000 | 1,321,000 | -10,522,000 | 8,735,000 | -780,000 | -2,945,000 | -2,945,000 | 10,778,000 | |||
net cash from operating activities | 395,000 | 10,028,000 | 14,044,000 | 14,044,000 | 98,615,000 | -8,010,000 | 17,945,000 | 24,114,000 | 24,114,000 | 135,382,000 | -11,556,000 | 31,887,000 | 21,113,000 | 21,113,000 | 135,986,000 | -1,389,000 | 15,128,000 | 31,853,000 | 31,853,000 | 124,412,000 | 3,720,000 | 21,987,000 | 24,766,000 | 24,766,000 | 49,031,000 | 28,870,000 | -4,796,000 | 6,120,000 | 6,120,000 | 48,691,000 | -4,986,000 |
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
free cash flows | 395,000 | 10,028,000 | 14,044,000 | 14,044,000 | 98,615,000 | -8,010,000 | 17,945,000 | 24,114,000 | 24,114,000 | 135,382,000 | -11,556,000 | 31,887,000 | 21,113,000 | 21,113,000 | 135,986,000 | -1,389,000 | 15,128,000 | 31,853,000 | 31,853,000 | 124,412,000 | 3,720,000 | 21,987,000 | 24,766,000 | 24,766,000 | 49,031,000 | 28,870,000 | -4,796,000 | 6,120,000 | 6,120,000 | 48,691,000 | -4,986,000 |
cash flows from investing activities: | |||||||||||||||||||||||||||||||
investment in short-term deposits | -128,904,000 | -89,797,000 | -23,390,000 | -23,703,000 | -31,297,000 | -31,297,000 | -54,101,000 | -79,140,000 | -94,000,000 | -6,000,000 | -6,000,000 | -25,590,000 | 611,000 | -23,111,000 | -23,111,000 | -5,090,000 | 1,000,000 | -21,000,000 | -21,000,000 | ||||||||||||
proceeds from short-term deposits | 48,390,000 | 23,703,000 | 31,297,000 | 31,297,000 | 80,600,000 | 124,640,000 | -6,500,000 | -14,910,000 | 100,500,000 | 6,000,000 | 6,000,000 | 7,090,000 | 3,000,000 | 20,000,000 | 20,000,000 | 5,000,000 | 90,000 | 19,000,000 | 19,000,000 | ||||||||||||
purchase of fixed assets | 85,000 | -134,000 | -85,000 | -85,000 | -592,000 | 169,000 | -134,000 | -112,000 | -112,000 | -556,000 | 45,000 | 147,000 | -341,000 | -341,000 | -1,188,000 | 174,000 | -262,000 | -299,000 | -299,000 | -685,000 | 84,000 | -173,000 | -165,000 | -165,000 | -360,000 | 123,000 | -127,000 | -99,000 | -99,000 | -639,000 | 32,000 |
purchase of marketable securities | -20,877,000 | -20,877,000 | -245,401,000 | -26,691,000 | 57,435,000 | -121,564,000 | -121,564,000 | -184,749,000 | -6,398,000 | 64,162,000 | -118,352,000 | -118,352,000 | -109,698,000 | -41,437,000 | 3,664,000 | -21,209,000 | -21,209,000 | -196,287,000 | -14,065,000 | -1,237,000 | -62,245,000 | -62,245,000 | -128,604,000 | -6,709,000 | 9,557,000 | -43,933,000 | -43,933,000 | -97,141,000 | -58,861,000 | ||
proceeds from sale of marketable securities | 3,003,000 | 3,003,000 | 68,521,000 | -11,677,000 | 20,445,000 | 13,465,000 | 13,465,000 | -18,933,000 | 6,004,000 | 3,305,000 | 11,927,000 | 11,927,000 | 87,917,000 | 9,480,000 | -5,622,000 | 26,802,000 | 26,802,000 | 122,236,000 | -28,212,000 | 15,138,000 | 38,574,000 | 38,574,000 | 59,074,000 | 11,500,000 | |||||||
proceeds from maturity of marketable securities | 6,230,000 | -20,272,000 | 62,147,000 | 62,147,000 | 234,820,000 | 33,279,000 | -2,428,000 | 92,118,000 | 92,118,000 | 174,764,000 | 17,574,000 | -30,246,000 | 91,137,000 | 91,137,000 | |||||||||||||||||
net cash from investing activities | -59,988,000 | -3,829,000 | 75,485,000 | 75,485,000 | 48,151,000 | 96,330,000 | 65,115,000 | -47,390,000 | -47,390,000 | -66,242,000 | -82,829,000 | 40,563,000 | -27,556,000 | -27,556,000 | -53,341,000 | 10,318,000 | -12,692,000 | -111,965,000 | -5,942,000 | -37,608,000 | -16,247,000 | -44,668,000 | 25,087,000 | -7,477,000 | -48,896,000 | ||||||
cash flows from financing activities: | |||||||||||||||||||||||||||||||
repurchase of ordinary shares | 72,476,000 | -99,960,000 | -99,960,000 | -208,829,000 | 12,424,000 | -42,637,000 | -42,637,000 | -10,193,000 | -864,000 | -864,000 | |||||||||||||||||||||
exercise of options | -256,000 | 11,000 | 494,000 | 494,000 | 2,049,000 | 170,000 | 161,000 | 234,000 | 234,000 | 2,775,000 | 1,902,000 | -846,000 | 1,673,000 | 1,673,000 | 1,002,000 | 346,000 | 43,000 | 161,000 | 161,000 | 15,143,000 | 489,000 | -5,181,000 | 9,892,000 | 9,892,000 | 4,078,000 | 149,000 | -1,452,000 | 2,001,000 | 2,001,000 | 211,000 | 163,000 |
net cash from financing activities | 27,228,000 | 72,487,000 | -99,466,000 | -99,466,000 | -206,780,000 | 12,594,000 | -88,819,000 | 234,000 | 234,000 | 2,775,000 | 1,902,000 | -846,000 | 1,673,000 | 1,673,000 | -41,635,000 | 346,000 | 42,680,000 | -42,476,000 | -42,476,000 | -20,222,000 | 11,546,000 | -15,374,000 | 9,028,000 | 9,028,000 | -13,140,000 | 149,000 | -1,452,000 | 2,001,000 | 2,001,000 | 211,000 | |
effect of exchange rate changes on cash and cash equivalents | -1,724,000 | 984,000 | 556,000 | 556,000 | -1,909,000 | 860,000 | 307,000 | -439,000 | -439,000 | 1,078,000 | |||||||||||||||||||||
net increase in cash and cash equivalents | -34,089,000 | -61,923,000 | 101,774,000 | 72,993,000 | -93,016,000 | 40,760,000 | -55,090,000 | -7,958,000 | 10,285,000 | 908,000 | -4,037,000 | -4,037,000 | 20,143,000 | -15,561,000 | 19,218,000 | 411,000 | 411,000 | 178,000 | 9,902,000 | ||||||||||||
cash and cash equivalents at beginning of period | 70,289,000 | -9,381,000 | 155,329,000 | 155,329,000 | -28,933,000 | -23,481,000 | 144,411,000 | 144,411,000 | 66,894,000 | -4,579,000 | 97,540,000 | 97,540,000 | 43,734,000 | -23,466,000 | 68,136,000 | 68,136,000 | -3,129,000 | -4,037,000 | 68,938,000 | 68,938,000 | 19,629,000 | 411,000 | 44,727,000 | 44,727,000 | |||||||
cash and cash equivalents at end of period | 36,200,000 | 70,289,000 | 145,948,000 | 145,948,000 | 72,841,000 | -28,933,000 | 120,930,000 | 120,930,000 | -26,122,000 | 66,894,000 | 92,961,000 | 92,961,000 | -11,356,000 | 43,734,000 | 44,670,000 | 44,670,000 | 7,156,000 | -3,129,000 | 64,901,000 | 64,901,000 | 4,068,000 | 19,629,000 | 45,138,000 | 45,138,000 | 19,828,000 | ||||||
decrease (increase) in accounts receivable | 3,953,000 | -4,569,000 | |||||||||||||||||||||||||||||
finance income | 1,261,000 | -1,574,000 | -1,574,000 | -283,000 | -4,757,000 | -4,757,000 | -346,000 | -749,000 | 40,000 | ||||||||||||||||||||||
decrease in other receivables | 474,000 | -1,560,000 | |||||||||||||||||||||||||||||
decrease (increase) in other receivables | -1,560,000 | ||||||||||||||||||||||||||||||
loss (gains) on marketable securities | -2,000 | -2,000 | -1,000 | 4,000 | 4,000 | ||||||||||||||||||||||||||
decrease in other liabilities | -3,287,000 | -3,287,000 | -7,803,000 | -7,803,000 | -23,043,000 | -23,043,000 | -4,875,000 | -4,875,000 | -795,000 | -795,000 | -1,793,000 | -1,793,000 | |||||||||||||||||||
net decrease in cash and cash equivalents | -9,381,000 | -9,381,000 | -23,481,000 | -23,481,000 | -4,579,000 | -4,579,000 | -23,466,000 | -23,466,000 | |||||||||||||||||||||||
deferred income tax assets | |||||||||||||||||||||||||||||||
other investments | |||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of year | |||||||||||||||||||||||||||||||
cash and cash equivalents at end of year | |||||||||||||||||||||||||||||||
cash and cash equivalents at | |||||||||||||||||||||||||||||||
beginning of the year | |||||||||||||||||||||||||||||||
end of the year | |||||||||||||||||||||||||||||||
supplemental disclosures of cash flows information: | |||||||||||||||||||||||||||||||
income taxes paid * | |||||||||||||||||||||||||||||||
interest received | |||||||||||||||||||||||||||||||
non-cash activities | |||||||||||||||||||||||||||||||
recognition of operating lease right-of-use assets and liabilities | |||||||||||||||||||||||||||||||
decrease in inventories | |||||||||||||||||||||||||||||||
decrease (increase) in inventories | -355,000 | ||||||||||||||||||||||||||||||
decrease in accounts payable | -743,000 | -743,000 | |||||||||||||||||||||||||||||
allowance for doubtful accounts | 165,000 | -92,000 | -68,000 | 210,000 | 210,000 | -239,000 | 247,000 | 40,000 | 40,000 | -146,000 | 306,000 | 306,000 | 23,000 | 36,000 | |||||||||||||||||
finance expense | |||||||||||||||||||||||||||||||
increase in accounts receivable | -5,331,000 | -2,804,000 | -3,489,000 | 1,321,000 | -897,000 | ||||||||||||||||||||||||||
acquisition of non-controlling interest in exchange of ordinary shares | |||||||||||||||||||||||||||||||
decrease in contract liabilities | |||||||||||||||||||||||||||||||
effect of exchange rate changes on cash | -131,000 | 191,000 | 191,000 | -250,000 | -288,000 | -926,000 | -151,000 | -151,000 | -183,000 | -390,000 | 237,000 | -223,000 | -223,000 | 499,000 | 88,000 | 379,000 | -233,000 | -233,000 | 172,000 | -100,000 | |||||||||||
investment in short-term deposit | -37,609,000 | -3,000,000 | 1,429,000 | -16,519,000 | -16,519,000 | ||||||||||||||||||||||||||
proceeds from short-term deposit | 28,090,000 | -6,870,000 | -910,000 | 14,500,000 | 14,500,000 | ||||||||||||||||||||||||||
finance expenses | -265,000 | 761,000 | 90,000 | 90,000 | -1,000 | 405,000 | 405,000 | ||||||||||||||||||||||||
net cash (used in) investing activities | -12,692,000 | -37,608,000 | -7,477,000 | ||||||||||||||||||||||||||||
change in allowance for doubtful accounts | |||||||||||||||||||||||||||||||
decrease in accrued contingencies | |||||||||||||||||||||||||||||||
proceeds from initial public offering of ordinary shares, net of offering costs | |||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of the year | |||||||||||||||||||||||||||||||
cash and cash equivalents at end of the year | |||||||||||||||||||||||||||||||
income taxes paid | |||||||||||||||||||||||||||||||
recognition of operating lease rou assets and liabilities | |||||||||||||||||||||||||||||||
changes in fair value of marketable securities | |||||||||||||||||||||||||||||||
increase in accrued contingencies | |||||||||||||||||||||||||||||||
deferred offering costs in accounts payable | |||||||||||||||||||||||||||||||
recognition of operating lease rou and liabilities | |||||||||||||||||||||||||||||||
gains on marketable securities | 3,000 | -6,000 | -6,000 | ||||||||||||||||||||||||||||
transaction with redeemable non-controlling interest | |||||||||||||||||||||||||||||||
stock-based compensation expense | -27,000 | ||||||||||||||||||||||||||||||
provision for deferred income taxes | |||||||||||||||||||||||||||||||
proceeds from initial public offering of ordinary shares, net of issuance costs | |||||||||||||||||||||||||||||||
beginning of period | |||||||||||||||||||||||||||||||
benefit from deferred income taxes | |||||||||||||||||||||||||||||||
increase (decrease) in accounts payable | |||||||||||||||||||||||||||||||
increase (decrease) in other liabilities | |||||||||||||||||||||||||||||||
increase (decrease) in contract liabilities | |||||||||||||||||||||||||||||||
net cash provided by financing activities |